Betulinic acid induces cytochrome c release and apoptosis in a Bax/Bak-independent, permeability transition pore dependent fashion
- First Online:
- Cite this article as:
- Mullauer, F.B., Kessler, J.H. & Medema, J.P. Apoptosis (2009) 14: 191. doi:10.1007/s10495-008-0290-x
Betulinic acid (BetA) is a plant-derived pentacyclic triterpenoid that exerts potent anti-cancer effects in vitro and in vivo, but is non toxic to untransformed cells. In our previous study we observed that BetA consistently induced cell death in a broad panel of tumor cell lines. Apoptosis induced by BetA involves activation of caspases, PARP cleavage and DNA fragmentation and was suggested to depend on the mitochondrial pathway. However, conflicting results have been reported with respect to the role of the pro- and anti-apoptotic members of the Bcl-2 family, which are often aberrantly regulated in tumors and thereby confer growth and survival advantages. Here we show that BetA-induced apoptosis critically depends on the release of cytochrome c from the mitochondria and formation of the apoptosome. Nevertheless, over-expression of Bcl-2 or Bcl-XL only provides limited protection against BetA-induced apoptosis. More importantly, Bax/Bak deficient cells are as sensitive to BetA as their wild-type counterparts, suggesting that cytochrome c is released in a non-classical fashion. In agreement, pre-incubation with cyclosporin A indicated a crucial role for the mitochondrial permeability transition pore (PT) in the induction of apoptosis. Our observations therefore indicate that BetA affects mitochondria and induces cytochrome c release directly via PT Pore. This is only temporarily prevented by anti-apoptotic members of the Bcl-2 family, but independent of Bax and Bak. These findings help to explain the remarkable broad efficacy of BetA against tumor cells of different origin and its effect in tumor cells that are resistant to other chemotherapeutic agents.
KeywordsBax Bak Bcl-2 family Betulinic acid Cell death Cytochrome c release
Betulinic acid (BetA) is a naturally occurring triterpenoid that has been initially described to specifically kill melanoma cells via induction of apoptosis  and was later shown to have specificity for neuroectoderm-derived tumors. However, it is becoming clear that its efficacy extends to many other cancer cell lines derived from a variety of different malignancies such as leukemia, prostate, ovarian, breast, lung, and colon cancer [2–6]. Importantly, BetA-induced apoptosis appears to be independent of p53 [6–8], but does show remarkable selectivity for tumor cells over non-transformed cells.
The extrinsic or death receptor pathway is not involved in BetA-induced apoptosis . However, formation of reactive oxygen species (ROS) and a decrease in the mitochondrial membrane potential have been repeatedly associated with BetA treatment [4, 10, 11], which prompted the hypothesis that BetA induces apoptosis via the mitochondrial pathway [12–14]. This pathway is normally regulated by a carefully balanced interplay between pro- and anti-apoptotic members of the Bcl-2 family. Over-expression of pro-survival molecules, such as Bcl-2, Bcl-XL or Mcl-1 or deletion of pro-apoptotic members, such as Bax and Bak, or alternatively deregulation of BH3-only molecules like Bim or Puma, is often observed in tumors and causes resistance of these cells to intrinsic death stimuli .
In agreement with a role for the mitochondria in BetA-induced apoptosis is the observation that over-expression of Bcl-2 or Bcl-XL prevents BetA-induced cytochrome c release, caspase activation and PARP cleavage in SHEP neuroblastoma cells [12, 13]. However, separate studies have shown that BetA rather increases the expression of Bcl-2, but can also modulate the expression of other pro- and anti-apoptotic Bcl-2 family members with distinct outcomes. For instance, Mcl-1 was strongly induced in melanoma cells after treatment with BetA , while expression of Bcl-XS and Bax were induced in neuroblastoma cells after treatment with BetA [7, 9]. These conflicting observations make it difficult to assess the role of the Bcl-2 family in BetA-induced apoptosis. Nevertheless, the broad anti-tumor effect of BetA renders it unlikely that induction of apoptosis would strictly depend on the classical Bcl-2 regulated mitochondrial pathway, as this is often disrupted in tumor cells [7, 15]. Previously we have shown that in Jurkat T leukemia cells apoptosis is induced upon incubation with BetA. Both classical and non-classical pathways to apoptosis exist [7, 16, 17] but the mechanism used by BetA remains incompletely defined. We therefore set out to delineate the signaling pathway and specifically the role of the Bcl-2 family regulated pathway in BetA-induced apoptosis in further detail. We show that Bcl-2 does not provide effective protection against BetA-induced apoptosis, especially not at later time points. Moreover, for the first time, we demonstrate that Bax/Bak double deficient mouse embryonic fibroblasts (Bax/Bak DKO MEFs) display cytochrome c release, caspase activation and PARP cleavage upon BetA treatment. This indicates that BetA does not induce a classical mitochondrial pathway to apoptosis. The mitochondria are critically involved though, as inhibition of the mitochondrial permeability transition (PT) pore by cyclosporin A (CsA) in combination with Bcl-2 over-expression provided effective protection from BetA induced apoptosis.
Materials and methods
Betulinic acid (≥99% pure, Bioservice Halle) was dissolved at 4 mg/ml in DMSO and aliquots were stored at −80°C. zVAD.fmk (benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone), etoposide, TMRE (Tetramethylrhodamine ethyl ester perchlorate), cyclosporin A and propidium iodide (PI) were purchased from Sigma–Aldrich. Anti-APO-1 was a kind gift from Dr. Peter Krammer.
For western blot analysis anti-caspase-3 (AF-605-NA, R&D and #9662, Cell Signaling) was used as well as an antibody specific for cleaved capsase-3 (Asp175, Cell Signaling) for mouse embryonic fibroblasts, furthermore anti-PARP (#9542, Cell Signaling), anti caspase-7 (#9492, Cell Signaling), anti-Bak (#06-536, Millipore), anti-Bax (N-20, Santa Cruz), anti Bcl-XL (B22630, BD; SC-634, Santa Cruz), and anti-Bcl-2 (N-19, Santa Cruz) were used. Anti-cytochrome c for FACS staining was obtained from BD (clone 6H2.B4).
Jurkat cells over-expressing Bcl-2, Bcl-XL and wild-type (wt) control cells were obtained from Dr. Jannie Borst (NKI, Amsterdam), MCF-7/FAS and MCF-7/FAS Bcl-2 or Bcl-XL were obtained from Dr. Marja Jäättelä (Danish Cancer Society, Copenhagen) . FADD-deficient, Casp-8- deficient and control Jurkat cells (JA3) were obtained from Dr. John Blenis (Harvard Medical School, Boston), Bax/Bak DKO MEFs and wild-type control MEFs were from Dr. Stanley Korsmeyer. APAF-1 and Caspase-9 knockout and wild-type MEFs were from Dr. Tak Mak (University of Toronto, Canada) and Dr. Richard Flavell (Yale, New Haven, USA), respectively. SW480 were provided by J. van Eendenburg and Dr. A. Gorter (department of Pathology, Leiden University Medical Center, The Netherlands), A549 were from ATCC, and HCT116 lines were from Dr. G. C. Chinnadurai (St Louis University School of Medicine, USA) and Dr. B. Vogelstein (Johns Hopkins, USA). All cells were cultured in IMDM supplemented with 8% FCS, 2 mM l-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin.
Western blot analysis
Cells were lysed in Triton X-100 buffer on ice and protein was quantified using a BCA kit from PIERCE according to manufactures protocol. A volume of 10–15 μg total protein was loaded per lane for SDS–PAGE and blotted onto PVDF transfer membrane (Amersham Biosciences). Blocking of unspecific binding sites was performed overnight at 4°C in 5% low fat milk powder in PBS/0.2% Tween-20 (blocking buffer), blots were then incubated with the primary antibody for 2 h at room temperature in blocking buffer, washed and incubated in blocking buffer with a secondary, HRP labeled antibody. For chemiluminescent visualization, ECL from Amersham Biosciences was used.
Cytochrome c release by FACS staining
Cytochrome c release assay was performed according to the protocol of Waterhouse [7, 19]. Briefly, cells were trypsinized, washed with PBS and incubated with 50 μg/ml digitonin in PBS with 100 mM KCl for 5–10 min. Permeabilization of the cell membrane was assessed using trypan blue exclusion. When the majority of the cells in the aliquot used for trypan blue staining were penetrated by the dye, cells were fixed in 4% paraformaldehyde in PBS for 30 min, washed and incubated in blocking buffer (3% BSA, 0.05% saponin, 0.02% azide in PBS supplemented with normal goat serum, dilution 1:200) for 1 h at room temparature. Anti-cytochrome c incubation was done overnight at 4°C, cells were washed three times and FITC conjugated secondary antibody was applied for 1 h at 4°C. After another washing step cells were analyzed by flow cytometry.
Assessment of mitochondrial membrane potential
Cells were incubated in growth medium containing 25 nM TMRE for 15–20 min at 37°C, resuspended in HEPES buffer, pH 7.4, containing 25 nM TMRE and analyzed by flow cytometry.
BetA-induced apoptosis depends on the apoptosome
The death receptor or extrinsic pathway is not involved in BetA-induced apoptosis [2, 9, 11, 20]. In agreement, Jurkat cells deficient in either FADD (FAS Associated Death Domain) or caspase-8, two crucial mediators in the extrinsic pathway, revealed similar sensitivity to BetA, whereas these cells were fully protected against CD95-induced apoptosis (Fig. 1b). These results suggest that BetA is able to induce caspase activation in a death receptor-independent and therefore likely a mitochondria dependent fashion. To validate whether the apoptosome, the signaling complex for capase-9 activation, is crucial for downstream caspase activation we used cells devoid of a functional apoptosome due to deletion of either Apaf-1 or caspase-9. MEFs lacking caspase-9 or Apaf-1 and wild-type MEFs were treated with various concentrations of BetA and apoptosis induction was analyzed after 24 h. Importantly, processing of both caspase-3 and PARP was blocked in caspase-9 deficient cells and in cells lacking Apaf-1 (Fig. 1c), indicating that the apoptosome is a key platform for downstream caspase activity in BetA-treated cells.
Anti-apoptotic Bcl-2 family members partially prevent BetA-induced apoptosis
Bax/Bak double deficient cells are sensitive to BetA-induced apoptosis
Cytochrome c is released upon BetA treatment in Bax/Bak DKO MEFs
BetA induced mitochondrial depolarization and apoptosis is dependent on the PT pore
The role of the mitochondrial permeability transition (PT) pore is controversial in apoptosis signaling. Some results strongly indicate that it is a secondary effect that is observed only upon downstream caspase activation, while other observations rather propose a causal role for the PT . Opening of the PT pore results in membrane depolarization and is suggested to also lead to cytochrome c release plus subsequent apoptosis. The composition of the pore that plays a role in apoptosis is still a matter of debate. Initial observations indicated that the pore consists of VDAC, ANT, and cyclophilin D . However, recent findings on knockouts lacking all ANT or VDAC forms suggest a more complicated picture [34, 35], at least when looking at the role of this pore in apoptosis. Nonetheless, induction of PT can be directly affected by Bcl-2 family members . We therefore tested the role of PT using TMRE to measure the mitochondrial membrane potential. We found that BetA induced a significant mitochondrial depolarization in Jurkat cells after 24 h, which was independent of caspase activation (Fig. 6b). Importantly, depolarization was reduced in cells over-expressing Bcl-2 (Fig. 6c). Etoposide, a more classical mitochondria-dependent compound, induced depolarization even more dramatic in control cells, but this effect was completely blocked by Bcl-2 (Fig. 6d) and to some extent caspase-dependent (not shown). This again points to the fact that BetA utilizes a different mechanism to target the mitochondria. To more directly analyze the involvement of the PT pore in BetA-induced apoptosis we made use of cyclosporin A (CsA), an inhibitor of cyclophilin D that prevents opening of the pore and thereby depolarization . In agreement, CsA reduced BetA-induced loss of TMRE staining by almost 50% in Jurkat control cells and completely prevented mitochondrial depolarization (Fig. 6c) and cytochrome c release (Fig. 6e) in Jurkat-Bcl-2 cells. In contrast, CsA did not have any protective effects on etoposide treated cells (Fig. 6d). More importantly, apoptosis as measured by DNA fragmentation after 72 h of BetA treatment was substantially inhibited by CsA alone and almost completely when it was combined with Bcl-2 over-expression (Fig. 6f).
BetA induced PT-pore dependent apoptosis is not cell type dependent
BetA is a very potent compound that is capable of killing a plethora of tumor cells. Here we demonstrate that BetA induces apoptosis in a manner that is dependent on the apoptosome, but is not affected by a lack of pro-apoptotic Bcl-2 family members Bax and Bak. BetA appears to target the mitochondrial PT pore directly and mitochondrial depolarization indeed is shown to be prevented by CsA. The anti-apoptotic Bcl-2 family members provide some protection, but this is at best limited and overcome at later time points. Multiple tumor cell lines have been shown to resist classical mitochondrial death pathways as they have a disturbed ratio of pro- and anti-apoptotic Bcl-2 family members . Our report now indicates that such disturbances are to a large extent irrelevant for the apoptosis induced by BetA.
Previous studies using the neuroblastoma cell line SHEP have demonstrated BetA-induced apoptosis to be completely abrogated by Bcl-2 over-expression [12, 13], which is in apparent contrast with our data. However, the same group showed that over-expression of Bcl-2 in Jurkat cells only provided about 65% protection after 24 h treatment . Similarly, it has been shown in two human glioma cell lines and in melanoma cells that over-expression of Bcl-2 only partially reduced caspase-3 activity and cell death after BetA-treatment [11, 20]. This observation is now corroborated by us, but extended to later time points and other cell lines. We found that the partial protective effect is not detected at all at later time points where the sensitivity to BetA in Bcl-2 over-expressing cells and wild-type cells was similar (Fig. 2c). It is important to note that this failure to protect is not due to the level of Bcl-2 (Fig. 2b) as etoposide-induced death is blocked at all time points tested (Fig. 2a). Previously, Chintharlapalli et al. [37, 38] reported that BetA directly affects transcription factors sp1, 3, and 4 and that this would lower transcription of survivin as well as Bcl-2. As such, BetA could lower Bcl-2 expression and thereby induce apoptosis. Although this is likely to affect sensitivity of tumor cells indirectly, we do not believe that this is the explanation for the differential sensitivity that we observe between BetA and etoposide. First and most important, Bcl-2 and Bcl-XL in our system are not dependent on their endogenous promoter, but on the strong CMV or EBV promoter and are thus not affected by sp1, 3, 4 down regulation. Secondly, even in the non-over-expressing Jurkat lines, we do not observe a decrease in Bcl-2 or Bcl-XL expression 24 h after BetA treatment.
The Bcl-2 independency of our system is even further supported by our observation that BetA-induced apoptosis is independent of the pro-apoptotic Bcl-2 family members Bax and Bak. In Bax/Bak DKO MEFs caspase-3 and PARP processing was induced with equal efficiency as in wild-type cells (Fig. 4d). Previously, Liby et al.  showed that Bax/Bak DKO MEFs were sensitive to BetA derivatives, but resisted BetA induced apoptosis. It is difficult to provide a rational for this discrepancy, especially as we also observe BetA-induced apoptosis in Bax/Bak deficient HCT-116 cells. We do observe a slight difference in cytochrome c release though, which is less pronounced in Bax/Bak DKO MEFs (Fig. 5a), but importantly, the amount of cells releasing cytochrome c is identical (Fig. 5b). The small difference in cytochrome c release is therefore either the result of less mitochondria per cell that release cytochrome c or that less cytochrome c is released per mitochondria. We believe this signifies the absence of an amplification loop initiated by active caspase-3, which cleaves Bid and thereby targets the mitochondria to induce maximal release. In agreement, caspase-8 processing occurs as an event downstream of the mitochondria in BetA treated neuroblastoma cells , and both caspase-8 and Bid-cleavage were shown for BetA treated Jurkat cells . Bcl-2 over-expression and Bax/Bak deficiency could therefore disallow this amplification and cells would thereby show less cytochrome c release.
Mitochondrial membrane depolarization is a heavily debated issue in apoptosis signaling. There is agreement on its occurrence, but the causal role for cytochrome c release is clearly disputed . We show that etoposide-induced loss of TMRE is blocked by Bcl-2 (Fig. 6d), and that BetA-induced depolarization is only partially prevented by Bcl-2 (Fig. 6c) but appears to serve a causal role as suggested by the inhibition of apoptosis by CsA (Fig. 6f). These observations point to a model in which BetA directly targets the pore and thereby allows cytochrome c release and downstream caspase activation. Bcl-2 family members have been shown to directly bind VDAC and regulate its pore forming activity. The pro-apoptotic member Bax promotes opening, while the anti-apoptotic members induce closure . A direct Bcl-2 family member-independent opening of the PT pore by BetA is consistent with our current observations. These would be independent of Bax and Bak, but could be hampered by Bcl-2 or Bcl-XL, which independently promote closure of the pore . The fact that CsA prevents pore opening and reduces apoptosis significantly, combined with the observation that this effect is complete in Bcl-2 over-expressing Jurkat cells adds to this hypothesis. It is important to note though that higher concentrations of CsA are capable of complete protection against BetA-induced apoptosis in three separate tumor lines. In Jurkat cells we failed to obtain full protection due to the high toxicity of CsA itself on these cells. However, A549 lung carcinoma cells, SW480 colon carcinoma cells as well as Bax/Bak deficient HCT-116 colon carcinoma cells all withstood CsA up to concentrations of 50 μg/ml and showed complete inhibition of BetA-induced apoptosis by CsA. Previous observations have shown that bongkrekic acid, a separate PT pore inhibitor, can also prevent BetA-induced cytotoxic effects  and thus support this model even further. We therefore believe that BetA targets the PT pore directly and thereby induces mitochondrial-dependent apoptosis. Other compounds, such as gossypol , A23187/ArA , and chelerythrine  have recently also been shown to induce Bax/Bak-independent cytochrome c release. Although for A23187/ArA-induced release this is suggested to be a serine protease dependent mechanism, chelerythrine, which shares some structural similarity with BetA, can induce release from isolated mitochondria. Although chelerythrine was developed as a Bcl-XL inhibitor, it also appears to induce mitochondrial permeabilization and apoptosis in Bax/Bak DKO cells, which is prevented by CsA . Combined, this may point to a mechanism in which the lipophilic characteristics of these compounds provide them with the means to target the outer mitochondrial membrane and thereby potentially affect the PT pore. In agreement with this idea is the observation that the PT pore opening is affected by the cholesterol content of the outer mitochondrial membrane . As cholesterol and BetA are structurally related, BetA could either modify this effect or have similar activity itself. Importantly, some tumor cells have been shown to contain higher cholesterol levels in their mitochondrial membrane and lowering this sensitizes them to apoptosis . More importantly, reconstituted PT pores in artificial membranes localize to cholesterol areas and can be opened using long chain fatty acids , indicating that lipids have a strong modulating effect on the pore.
Although these data provide an appealing explanation for the broad effects of BetA on tumor cells, it still remains difficult to understand why it is without effect on untransformed cells. As mentioned, the lipid content of the mitochondria in tumor cells may be different to some extent, but this is unlikely to explain the selectivity for tumor cells. Especially as the changes observed in tumor cells rather prevent then facilitate apoptosis induction. It is possible though that another component associated with the PT-pore is a crucial determinant in the toxicity exerted by BetA. This component, hexokinase is associated with the pore on the cytoplasmic side and regulates pore opening as well as the level of glycolysis in a cell . It is well established that tumor cells mainly utilize glycolysis for their ATP generation. This so called Warburg effect is potentially regulated by a differential expression level of hexokinase II in tumor versus normal cells . Inactivation of hexokinase II using 3-bromopyruvate displays similar tumor selectivity as BetA .
In summary, we conclude that our study provides an explanation as to why BetA is a very effective and broadly applicable anti-cancer agent, even against tumor cells which have acquired resistance to other, Bcl-2 family dependent, apoptosis inducing treatments. Future experiments will provide more mechanistic insight into the exact mechanism by which BetA modulates the PT-pore and whether the tumor selectivity involves PT pore sensitivity and/or hexokinase activity.
We would like to thank Jannie Borst (NKI, Amsterdam, The Netherlands), Marja Jäättelä (Danish Cancer Society, Copenhagen, Denmark), John Blenis (Harvard, Boston, USA), Stanley Korsmeyer, Tak Mak (University of Toronto, Canada), Richard Flavell (Yale, New Haven, USA), Bert Vogelstein (Johns Hopkins University) and Chinna Chinnadurai (St Louis School of Medicine) for their kind and rapid actions in providing cells that were of great value to this study and Eric Eldering (AMC, Amsterdam, The Netherlands) for anti Bak antibody. This work was supported by a grant of the Stichting Nationaal Fonds tegen Kanker (SNFK), Amsterdam, The Netherlands.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.